2021 has been an interesting and busy year for the Seratec team.  

We've celebrated over 20 years of supply of our antibody reagents, standards and test kits to MilkTest NZ for use in their Bovine IgG quantification assays. 

We've also worked with our University of Otago colleagues in formulating SARS CoV-2 peptide immunisation adjuvants for use in the raising of polyclonal antibodies for the development of novel Covid-19 antigen and  antibody assays.  Funding for this project was provided by the NZ Ministry of Business, Innovation & Employment to the University of Otago.  Titermax Gold adjuvant was compared alongside our own immunisation/adjuvant regime.   

Seratec's SARS CoV-1 antibody cocktails (recombinant and peptides) originally formulated way back in 2003 were also validated to react against SARS CoV-2 (COVID-19).  The same antibody formulations were shown to neutralize SARS CoV-1 via collaboration studies performed in 2004 by the Hauptman-Woodward Institute when Chris was at Virionyx Corporation.  At that time polyclonal antibodies were raised employing a proprietary microparticle adjuvant conjugated with SARS peptide and recombinant combinations.

Relevant Publications

Quantitative anti-PA IgG ELISA; assessment and comparability with the anthrax toxin neutralization assay in goats.

BMC Veterinary Research 2013 9:265  Published: 27 December 2013

MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity.

Vaccine. 2011 Jan 10;29(3):545-57. doi: 10.1016/j.vaccine.2010.10.040. Epub 2010 Oct 27.

The Therapeutic Vaccine Potential of MIS416 Adjuvant.

Biopharm International, Vol 2009 Supplement, Issue 1.


Rapid generation of an anthrax immunotherapeutic rom goats using a novel non-toxic muramyl dopeptide adjuvant.